Pharmacokinetic properties and bioequivalence of orally inhaled salbutamol in healthy Chinese volunteers

References

• Patel M, Thomson NC. (R)-salbutamol in the treatment of asthma and chronic obstructive airways disease. Expert Opin Pharmacother 2011;12:1133–41.
   PubMed Web of Science ®Google Scholar
• Tukiainen H, Jaakkola J, Torkko M, Terho EO. Comparison between oral procaterol and salbutamol in patients with bronchial asthma. Curr Med Res Opin 1988;11:236–41.
   PubMed Web of Science ®Google Scholar
• O’Connor D, Adams WP, Chen ML, et al. Role of pharmacokinetics in establishing bioequivalence for orally inhaled drug products: workshop summary report. J Aerosol Med Pulm Drug Deliv 2011;24:119–35.
   PubMedGoogle Scholar
• Lipworth BJ. Pharmacokinetics of inhaled drugs. Br J Clin Pharmacol 1996;42:697–705.
   PubMed Web of Science ®Google Scholar
• Apiou-Sbirlea G, Newman S, Fleming J, et al. Bioequivalence of inhaled drugs: fundamentals, challenges and perspectives. Ther Deliv 2013;4:343–67.
   PubMedGoogle Scholar
• European Medicines Agency. Committee for Medicinal Products for Human Use, “Requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of Asthma and Chronic Obstructive Pulmonary Disease (COPD) in adults and for use in the treatment of asthma in children and adolescents”; 2009. Available from: www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003551.pdf [last accessed 19 Mar 2008].
   Google Scholar
• European Medicines Agency. Committee for Medicinal Products for Human Use, “Guideline on the investigation of bioequivalence”, Draft; 2008. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf [last accessed 20 Jan 2010].
   Google Scholar
• U.S. Department of Health and Human Services Food and Drug Administration. Guidance for Industry, “Bioavailability and Bioequivalence Studies for Nasal Aerosols and Nasal Sprays for Local Action”, Draft; 2003. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070111.pdf [last accessed Apr 2003].
   Google Scholar
• Lumry W, Noveck R, Weinstein S, et al. Switching from Ventolin CFC to Ventolin HFA is well tolerated and effective in patients with asthma. Ann Allergy Asthma Immunol 2001;86:297–303.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. ICH Topic E 6(R1). Guideline for Good Clinical Practice; 2006. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002874.pdf [last accessed Jul 2002].
   Google Scholar
• World Medical Association. Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects; 2008. Available from: http://www.wma.net/en/30publications/10policies/b3/index.html [last accessed Oct 2008].
   Google Scholar
• Ma M, Chen X, Guo L, Zhong D. Determination of salbutamol in human plasma after aerosol inhalation using hydrophilic interaction chromatography (HILIC) – tandem mass spectrometry. Chin J Pharm Anal 2013;33:929–34.
   Google Scholar
• China Food and Drug Administration. Guidance on the investigation of bioavailability and bioequivalence; 2005. Available from: http://www.cde.org.cn/zdyz.do?method=largePage&id=2066 [last accessed 23 Aug 2007].
   Google Scholar
• Liu JP, Chow SC. Sample size determination for the two one-sided tests procedure in bioequivalence. J Pharmacokinet Biopharm 1992;20:101–4.
   PubMedGoogle Scholar
• Hindle M, Chrystyn H. Determination of the relative bioavailability of salbutamol to the lung following inhalation. Br J Clin Pharmacol 1992;34:311–15.
   PubMed Web of Science ®Google Scholar
• Hindle M, Chrystyn H. Relative bioavailability of salbutamol to the lung following inhalation using metered dose inhalation methods and spacer devices. Thorax 1994;49:549–53.
   PubMed Web of Science ®Google Scholar
• Lähelmä S, Kirjavainen M, Kela M, et al. Equivalent lung deposition of budesonide in vivo: a comparison of dry powder inhalers using a pharmacokinetic method. Br J Clin Pharmacol 2005;59:167–73.
   PubMed Web of Science ®Google Scholar
• Persson G, Ankerst J, Gillen M, et al. Relative systemic availability of budesonide in patients with asthma after inhalation from two dry powder inhalers. Curr Med Res Opin 2008;24:1511.
   PubMed Web of Science ®Google Scholar
• Tomlinson HS, Corlett SA, Chrystyn H. Dose-response relationship and reproducibility of urinary salbutamol excretion during the first 30 min after an inhalation. Br J Clin Pharmacol 2003;56:225–7.
   PubMed Web of Science ®Google Scholar
• Daley-Yates PT1, Parkins DA. Establishing bioequivalence for inhaled drugs; weighing the evidence. Expert Opin Drug Deliv 2011;8:1297–308.
   PubMed Web of Science ®Google Scholar
• Daley-Yates PT, Mehta R, Chan RH, et al. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients. J Aerosol Med Pulm Drug Deliv 2014;27:279–89.
   PubMed Web of Science ®Google Scholar
• Adams WP, Ahrens RC, Chen ML, et al. Demonstrating bioequivalence of locally acting orally inhaled drug products (OIPs): workshop summary report. J Aerosol Med Pulm Drug Deliv 2010;23:1–29.
   PubMedGoogle Scholar
• Melchor R, Biddiscomb MF, Mak VHF, Spiro SG. Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airflow obstruction. Thorax 1993;48:506–11.
   PubMed Web of Science ®Google Scholar
• Chrystyn H. Is total particle dose more important than particle distribution? Respir Med 1997;91(Suppl A):17–19.
   PubMed Web of Science ®Google Scholar
• Mackie AE, McDowall JE, Falcoz C, et al. Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in healthy volunteers. Clin Pharmacokinet 2000;39(Suppl 1):23–30.
   PubMed Web of Science ®Google Scholar
• Falcoz C, Horton J, Mackie AE, et al. Pharmacokinetics of fluticasone propionate inhaled via the Diskhaler and Diskus powder devices in patients with mild-to-moderate asthma. Clin Pharmacokinet 2000;39(Suppl 1):31–7.
   PubMed Web of Science ®Google Scholar
• Leach CL. Improved delivery of inhaled steroids to the large and small airways. Respir Med 1998;92(Suppl A):3–8.
   PubMed Web of Science ®Google Scholar
• Evans C, Cipolla D, Chesworth T, et al. Equivalence considerations for orally inhaled products for local action-ISAM/IPAC-RS European Workshop report. J Aerosol Med Pulm Drug Deliv 2012;25:117–39.
   PubMed Web of Science ®Google Scholar
• Borgstroem L, Nilsson M. A method for determination of the absolute pulmonary bioavailability of inhaled drugs: terbutaline. Pharm Res 1990;7:1068–70.
   PubMed Web of Science ®Google Scholar
• Argenti D, Shah B, Heald D. A pharmacokinetic study to evaluate the absolute bioavailability of triamcinolone acetonide following inhalation administration. J Clin Pharmacol 1999;39:695–702.
   PubMed Web of Science ®Google Scholar
• Thorsson L, Edsbäcker S, Conradson TB. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. Eur Respir J 1994;7:1839–44.
   PubMed Web of Science ®Google Scholar
• Grekas N, Athanassiou K, Papataxiarchou K, et al. Pharmacokinetic study for the establishment of bioequivalence of two inhalation treatments containing budesonide plus formoterol. J Pharm Pharmacol 2014;66:1677–85.
   PubMed Web of Science ®Google Scholar
• Du XL, Zhu Z, Fu Q, Li DK. Bioequivalent evaluation of two salbutamol aerosols by pharmacokinetics method sampling over 20 minutes. Chin Pharm J 2002;37:689–91.
   Google Scholar
• Zhang D, Teng Y, Chen K. Determination of salbutamol in human plasma and urine using liquid chromatography coupled to tandem mass spectrometry and its pharmacokinetic study. Biomed Chromatogr 2012;26:1176–82.
   PubMed Web of Science ®Google Scholar
• Clark DJ, Gordon-Smith J, McPhate G, et al. Lung bioavailability of generic and innovator salbutamol metered dose inhalers. Thorax 1996;51:325–6.
   PubMed Web of Science ®Google Scholar
• Lipworth BJ, Clark DJ. Lung delivery of salbutamol given by breath activated pressurized aerosol and dry powder inhaler devices. Pulm Pharmacol Ther 1997;10:211–14.
   PubMed Web of Science ®Google Scholar